Literature DB >> 3979914

Lactitol in the treatment of chronic hepatic encephalopathy: an open comparison with lactulose.

P L Lanthier, M Y Morgan.   

Abstract

Lactulose is currently the drug of choice for the treatment of hepatic encephalopathy. It is, however, only available as a syrup which is contaminated with other sugars. Consequently patients may express aversion to its excessively sweet taste and many experience nausea because of its hyperosmolarity. Lactitol is a disaccharide analogue of lactulose which can be produced as a pure crystalline powder with a low relative sweetness. Theoretically it should have the same therapeutic effects as lactulose but fewer side effects. Five patients with chronic hepatic encephalopathy on maintenance lactulose were monitored clinically, psychometrically, and by measurement of venous blood ammonia, electroencephalogram mean cycle frequency, and cerebral blood flow during three months treatment with lactulose and a similar period on lactitol. Lactitol was at least as efficacious as lactulose but was more acceptable because its cathartic effect was more predictable, its formulation was more convenient and its less sweet taste preferred. Lactitol is the ideal successor to lactulose for treatment of this condition.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3979914      PMCID: PMC1432513          DOI: 10.1136/gut.26.4.415

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  10 in total

1.  Hypernatremia after the administration of lactulose.

Authors:  C Kaupke; T Sprague; G L Gitnick
Journal:  Ann Intern Med       Date:  1977-06       Impact factor: 25.391

2.  Trailmaking and number-connection tests in the assessment of mental state in portal systemic encephalopathy.

Authors:  H O Conn
Journal:  Am J Dig Dis       Date:  1977-06

Review 3.  Hepatic encephalopathy.

Authors:  A M Hoyumpa; P V Desmond; G R Avant; R K Roberts; S Schenker
Journal:  Gastroenterology       Date:  1979-01       Impact factor: 22.682

4.  The Revised Kendrick Battery: clinical studies.

Authors:  D C Kendrick; A J Gibson; I C Moyes
Journal:  Br J Soc Clin Psychol       Date:  1979-09

5.  Food additives derived from lactose: lactitol and lactitol palmitate.

Authors:  J A van Velthuijsen
Journal:  J Agric Food Chem       Date:  1979 Jul-Aug       Impact factor: 5.279

6.  Treatment of chronic portal-systemic encephalopathy with lactulose.

Authors:  J Bircher; J Müller; P Guggenheim; U P Haemmerli
Journal:  Lancet       Date:  1966-04-23       Impact factor: 79.321

7.  Two minute slope inhalation technique for cerebral blood flow measurement in man. 1. Method.

Authors:  D J Wyper; G A Lennox; J O Rowan
Journal:  J Neurol Neurosurg Psychiatry       Date:  1976-02       Impact factor: 10.154

8.  Method for measuring cerebral dysfunction in patients with liver disease.

Authors:  R Zeegen; J E Drinkwater; A M Dawson
Journal:  Br Med J       Date:  1970-06-13

9.  Lactulose--a drug with antiendotoxin effect.

Authors:  H Liehr; G Englisch; U Rasenack
Journal:  Hepatogastroenterology       Date:  1980-10

10.  [1st use of lactitol in the treatment of porto-systemic encephalopathy].

Authors:  J Bircher; M Bührer; K Franz; J A van Velthuijsen
Journal:  Schweiz Med Wochenschr       Date:  1982-09-18
  10 in total
  18 in total

1.  Effects of lactulose and lactitol on protein digestion and metabolism in conventional and germ free animal models: relevance of the results to their use in the treatment of portosystemic encephalopathy.

Authors:  S P Bird; D Hewitt; B Ratcliffe; M I Gurr
Journal:  Gut       Date:  1990-12       Impact factor: 23.059

Review 2.  Nutritional support in liver disease.

Authors:  D B Silk; S J O'Keefe; C Wicks
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

Review 3.  Management of overt hepatic encephalopathy.

Authors:  Praveen Sharma; Barjesh C Sharma
Journal:  J Clin Exp Hepatol       Date:  2014-05-10

Review 4.  Branched chain amino acids in liver disease: fact or fantasy?

Authors:  D B Silk
Journal:  Gut       Date:  1986-11       Impact factor: 23.059

Review 5.  Chronic portal systemic encephalopathy: update 1987.

Authors:  S Sherlock
Journal:  Gut       Date:  1987-08       Impact factor: 23.059

Review 6.  Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis.

Authors:  Lise Lotte Gluud; Hendrik Vilstrup; Marsha Y Morgan
Journal:  Cochrane Database Syst Rev       Date:  2016-05-06

7.  Lactitol, a second-generation disaccharide for treatment of chronic portal-systemic encephalopathy. A double-blind, crossover, randomized clinical trial.

Authors:  M Uribe; H Toledo; F Perez; F Vargas; S Gil; G Garcia-Ramos; G P Ravelli; L Guevara
Journal:  Dig Dis Sci       Date:  1987-12       Impact factor: 3.199

8.  Lactitol in treatment of chronic hepatic encephalopathy. A meta-analysis.

Authors:  C Cammà; F Fiorello; F Tinè; G Marchesini; A Fabbri; L Pagliaro
Journal:  Dig Dis Sci       Date:  1993-05       Impact factor: 3.199

Review 9.  Disaccharides in the treatment of hepatic encephalopathy.

Authors:  Praveen Sharma; Barjesh Chander Sharma
Journal:  Metab Brain Dis       Date:  2013-03-02       Impact factor: 3.584

10.  Lactitol: gastrointestinal absorption and effect on blood lactate in healthy volunteers and patients with cirrhosis.

Authors:  J Metzger; C Chollet; M Wermeille; J Biollaz; J B Llull; B H Lauterburg
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.